Literature DB >> 17397240

Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B.

Cécile Ménez1, Philippe Legrand, Véronique Rosilio, Sylviane Lesieur, Gillian Barratt.   

Abstract

This study describes the interactions between two amphiphilic molecules with antileishmanial activity, amphotericin B (AmB) and miltefosine [hexadecylphosphocholine (HePC)], the latter being effective by the oral route. The effect of HePC on the aggregation state of AmB in aqueous solution and the interactions between the two agents were monitored using absorption spectroscopy and circular dichroism. Structural characterization of the mixed aggregates formed in water by dynamic light scattering (DLS) and cryofracture electron microscopy was performed. At concentrations above its critical micelle concentration, HePC was shown to interact with AmB, leading to an increase in the proportion of AmB in its monomeric form as a result of a micellar solubilization mechanism with a capacity of 26 +/- 3 mmol of AmB solubilized/mol of HePC, that is, nearly 40 molecules of HePC per molecule of AmB in the mixed micelles. These were revealed as individual and spherical aggregates close to 10 nm in diameter by both electron microscopy and DLS. Such a micellar formulation provides a new AmB-based system which might be useful in delivering AmB orally for visceral leishmaniasis bitherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17397240     DOI: 10.1021/mp0601143

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

2.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

3.  Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.

Authors:  Anke E Kip; Séverine Blesson; Fabiana Alves; Monique Wasunna; Robert Kimutai; Peninah Menza; Bewketu Mengesha; Jos H Beijnen; Asrat Hailu; Ermias Diro; Thomas P C Dorlo
Journal:  J Antimicrob Chemother       Date:  2021-04-13       Impact factor: 5.790

4.  Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization.

Authors:  Bushra T Al-Quadeib; Mahasen A Radwan; Lidija Siller; Benjamin Horrocks; Matthew C Wright
Journal:  Saudi Pharm J       Date:  2014-11-20       Impact factor: 4.330

Review 5.  Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Authors:  Anke E Kip; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

6.  Integral Role of Water in the Solid-State Behavior of the Antileishmanial Drug Miltefosine.

Authors:  Amy V Hall; Isobel E F Gostick; Dmitry S Yufit; Gloria Y Marchant; Preyanthiny Kirubakaran; Shadrack J Madu; Mingzhong Li; Patrick G Steel; Jonathan W Steed
Journal:  Cryst Growth Des       Date:  2022-09-20       Impact factor: 4.010

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.